UCL School of Pharmacy

Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Retrieved on: 
Thursday, August 17, 2023

Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.

Key Points: 
  • Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.
  • Tariq Arshad, M.D., M.B.A., Chief Medical Officer, stated: “I am delighted that the FDA has cleared QN-302 to enter the clinic for the proposed Phase 1 clinical trial in patients with advanced or metastatic patients with solid tumors.
  • TD2, our CRO partner, has been instrumental in bringing us to this point.
  • Qualigen will enroll patients with advanced or metastatic solid tumors who have failed prior therapy.

Husson University’s School of Pharmacy Ranked among the Top 20 Pharmacy Schools by Becker’s Hospital Review

Retrieved on: 
Tuesday, May 9, 2023

[2]

Key Points: 
  • [2]
    “We are honored to be included in this pharmacy school ranking,” said Dr. James Nash, dean of Husson University’s College of Health and Pharmacy.
  • Graduates from the Husson University School of Pharmacy have an outstanding reputation as being among some of the finest in Maine.
  • The School of Pharmacy is just one of several schools that are a part of Husson University’s College of Health and Pharmacy.
  • [3] Becker’s Hospital Review, “About Us,” https://www.beckershospitalreview.com/about.html , Accessed: April 17, 2023
    [4] NABP: National Association of Boards of Pharmacy, “About,” https://nabp.pharmacy/about/ , Accessed, April 17, 2023

Prescient Announces Recent Senior Appointments to Its Medical Team

Retrieved on: 
Wednesday, March 29, 2023

LONDON, March 29, 2023 /PRNewswire/ -- Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Navi Singh Parmar, Michaela Scheiner, and Dr. Sanam Sikander-Rehman as leaders in Prescient Medical.

Key Points: 
  • Prescient hires three new senior members to support its growing Medical Center of Excellence.
  • LONDON, March 29, 2023 /PRNewswire/ -- Prescient, a biopharma product and portfolio strategy firm, has announced the recent appointments of Navi Singh Parmar, Michaela Scheiner, and Dr. Sanam Sikander-Rehman as leaders in Prescient Medical.
  • At Prescient, Navi assists both Commercial and Medical clients to solve strategic challenges across various therapeutic areas.
  • Michaela has successfully supported medical education, strategy and information, functional design and medical governance projects.

Research by Husson Pharmacy Faculty and PCHC Colleague Describes Second-Year Pharmacy Residency Growth

Retrieved on: 
Thursday, March 9, 2023

The research was completed by two faculty members from the Husson University School of Pharmacy.

Key Points: 
  • The research was completed by two faculty members from the Husson University School of Pharmacy.
  • They are Dr. Drew Lambert, BCPS, an associate professor of pharmacy practice and Dr. Shannon M. James, BCPP, an assistant professor of pharmacy practice.
  • Prior to joining PCHC , Welch was an assistant professor of pharmacy practice at Husson’s School of Pharmacy from August 2019 - August 2021.
  • The School of Pharmacy is just one of several schools that are a part of Husson University’s College of Health and Pharmacy.

Eurocine Vaccines' Director of Preclinical Development invited to lecture at UCL School of Pharmacy

Retrieved on: 
Monday, February 20, 2023

SOLNA, Sweden, Feb. 20, 2023 /PRNewswire/ -- Eurocine Vaccines ("Eurocine" or the "Company") announces today that the Company's Director of Preclinical Development, Dr. Karl Ljungberg, has lectured on DNA and RNA vaccines at one of the top ranked pharmacy schools in the UK.

Key Points: 
  • SOLNA, Sweden, Feb. 20, 2023 /PRNewswire/ -- Eurocine Vaccines ("Eurocine" or the "Company") announces today that the Company's Director of Preclinical Development, Dr. Karl Ljungberg, has lectured on DNA and RNA vaccines at one of the top ranked pharmacy schools in the UK.
  • On February 16, Dr. Karl Ljungberg, the Company's Director of Preclinical Development, was invited by Dr. Martinez Bravo to lecture at University College London, UCL School of Pharmacy, one of the UK's top-ranked pharmacy schools.
  • As part of a course module in "Applications of Immunology: Immunotherapy, vaccines and diagnostic techniques," Dr. Karl Ljungberg was invited to lecture on DNA and RNA vaccines.
  • "It is of course gratifying that our Director of Preclinical Development has been invited to lecture at such a highly ranked university as UCL School of Pharmacy as it clearly indicates that Eurocine Vaccines is at the forefront of vaccine development and that our in-house expertise is sought after in the academic world," says CEO Hans Arwidsson.

SIUE School of Pharmacy Ranks No. 1 Regionally and Top 25 in U.S.

Retrieved on: 
Tuesday, June 14, 2022

EDWARDSVILLE, Ill., June 14, 2022 /PRNewswire-PRWeb/ -- Southern Illinois University Edwardsville's School of Pharmacy (SOP) graduates have again exceeded state and national first-attempt pass rates on licensure exams, extending the program's status as number one in Illinois and Missouri and among the top 25 in the country.

Key Points: 
  • The North American Pharmacist Licensure Exam (NAPLEX) and the Illinois Multistate Pharmacy Jurisprudence Examination (MPJE) are components of the licensing process for pharmacists in the United States.
  • The Class of 2021's first-attempt NAPLEX pass rate is 91%, compared to 84% national average and a state average of 75%.
  • Its first-attempt pass rate for the Illinois MPJE is 89%, outpacing the 80% national average and 73% state average.
  • Areas of excellence include a drug design and discovery core, pediatric practice, chronic pain research and practice, and diabetes research and practice.

Virpax Successfully Completes Initial Preclinical Studies for VRP324

Retrieved on: 
Tuesday, April 26, 2022

In this preclinical PK study, VRP324 was able to deliver cannabidiol (CBD) to the brain after nasal administration in a rodent model.

Key Points: 
  • In this preclinical PK study, VRP324 was able to deliver cannabidiol (CBD) to the brain after nasal administration in a rodent model.
  • Nasal delivery of VRP324 provided high concentrations of CBD in the brain and the preclinical studies confirm that there were higher levels of CBD in the brain versus the plasma.
  • VRP324 uses a preassembled device and cartridge to propel the MET-CBD powder formulation into the nose via the olfactory nerve/bulb.
  • Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement

Retrieved on: 
Tuesday, March 15, 2022

Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.

Key Points: 
  • Virpax Pharmaceuticals, Inc. (Virpax or the Company) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.
  • This assists us with the transition of AnQlar to a potential over-the-counter designation by the FDA, stated Christopher M. Chipman, CFO and Secretary of Virpax.
  • Obtaining the worldwide rights to AnQlar is consistent with our global business model and puts the company in a stronger position to pursue strategic alliances or enterprise opportunities for this product candidate, commented Anthony P. Mack, Chairman & CEO of Virpax.
  • AnQlar (GCPQ) is a positively-charged chitosan derivative that binds electrostatically to negatively charged viruses such as SARS-CoV-2 and influenza.

Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302

Retrieved on: 
Tuesday, February 1, 2022

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company’s in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform. Qualigen is developing this platform’s lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers.

Key Points: 
  • Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Companys in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform.
  • Professor Neidle will play an integral role as a scientific advisor by working with our Chief Medical Officer, Dr. Tariq Arshad and the Qualigen team as we advance QN-302 toward the clinic.
  • He will also serve to build scientific understanding regarding data results, including authorship and presentation to the scientific community.
  • Finally, we hope to leverage Professor Neidles experience in discovery and development of drugs that have been granted Fast Track designation by the FDA.

Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics

Retrieved on: 
Tuesday, January 18, 2022

CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data and a patent estate, from University College London (UCL). Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. This license agreement was carried out by UCL Business Limited, the commercialization company for UCL.

Key Points: 
  • Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers.
  • This program aligns with our oncology focused therapeutics pipeline, expands our IP portfolio, and positions Qualigen well in this exciting area of G4 cancer research, commented Michael Poirier, Qualigens Chief Executive Officer.
  • The scientific work UCL completed on the G4 platform could enable us to proceed with IND-enabling studies in 2022 toward an initial indication of pancreatic cancer.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.